Johnson & Johnson History & Founding Timeline

J&J's attempt to resolve talc-related ovarian cancer and mesothelioma litigation through the LTL Management subsidiary bankruptcy strategy — creating a new subsidiary to hold the talc liabilities and then filing for bankruptcy protection — was rejected by federal courts twice as an improper use of bankruptcy protection by a financially healthy parent company. The strategy, intended to achieve comprehensive liability resolution efficiently, instead prolonged litigation uncertainty, generated adverse media coverage, and consumed management attention without achieving its legal objective, representing a strategic miscalculation about judicial receptivity to the novel liability management approach.

J&J's DePuy Orthopaedics recalled its ASR hip resurfacing and XL Acetabular hip replacement systems in 2010 following elevated failure rates linked to metal ion release from metal-on-metal implant surfaces. The recalls and subsequent litigation generated approximately 4+ billion USD in settlements and legal costs, and more significantly damaged DePuy's brand reputation in the orthopedic surgery community — requiring years of relationship rebuilding with orthopedic surgeons who had experienced patient complications from the defective implants.

J&J's decision to separate the consumer health segment into Kenvue, while strategically sound in retrospect, was delayed relative to the point at which the strategic logic became clear — with the consumer business's lower growth and margin profile depressing J&J's overall valuation multiple for years before the separation was executed. Earlier separation would have unlocked higher valuation multiples for the pharmaceutical and MedTech businesses sooner and provided the consumer health segment with management focus and capital allocation independence earlier in the competitive evolution of the consumer health market.